Legalize
Legalize / United Kingdom / Wales / Welsh-Statutory-Instrument

The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004

Type Welsh-Statutory-Instrument
Publication 2004-03-30
Last updated 2024-11-15
State In force
Jurisdiction Wales
Department King's Printer of Acts of Parliament
Source legislation.gov.uk
PDF Download
articles Not indexed
Reform history JSON API

SCHEDULE 2 — DRUGS OR MEDICINES TO BE ORDERED ONLY IN CERTAIN CIRCUMSTANCES

Column 1 Column 2 Column 3
Drugs Patient Condition
In this Schedule— ... “at-risk” means in relation to a patient, a patient who— has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);has significant cardiovascular disease, excluding a patient who has hypertension only;has chronic renal disease;is immunocompromised;has diabetes mellitus;has chronic liver disease; orhas chronic neurological disease; ... “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992[^f00006] as adjusted by the Protocol signed at Brussels on 17th March 1993[^f00007] and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994[^f00008];“EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. ... “GnRH analogue” means gonadotrophin-releasing hormone, a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin; “Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza; “patient” has the same meaning as in the National Health Services (General Medical Service Contracts) (Wales) Regulations 2023; “residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care. In this Schedule— ... “at-risk” means in relation to a patient, a patient who— has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);has significant cardiovascular disease, excluding a patient who has hypertension only;has chronic renal disease;is immunocompromised;has diabetes mellitus;has chronic liver disease; orhas chronic neurological disease; ... “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992[^f00006] as adjusted by the Protocol signed at Brussels on 17th March 1993[^f00007] and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994[^f00008];“EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. ... “GnRH analogue” means gonadotrophin-releasing hormone, a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin; “Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza; “patient” has the same meaning as in the National Health Services (General Medical Service Contracts) (Wales) Regulations 2023; “residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care. In this Schedule— ... “at-risk” means in relation to a patient, a patient who— has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);has significant cardiovascular disease, excluding a patient who has hypertension only;has chronic renal disease;is immunocompromised;has diabetes mellitus;has chronic liver disease; orhas chronic neurological disease; ... “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992[^f00006] as adjusted by the Protocol signed at Brussels on 17th March 1993[^f00007] and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994[^f00008];“EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. ... “GnRH analogue” means gonadotrophin-releasing hormone, a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin; “Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza; “patient” has the same meaning as in the National Health Services (General Medical Service Contracts) (Wales) Regulations 2023; “residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care.
Clobazam Any patient Treatment of epilepsy
. . . . . . . . .
GnRH analogue 1Any patient who is aged 18 or over.2Any patient who is aged under 18 who is receiving treatment under a general medical services contract which does not include treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.3Any patient who is aged under 18, and who—abefore 19 July 2024, started a course of treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both, and in this context, a person is treated as having started a course of treatment with a GnRH analogue if, on or after 3 December 2023, that person was issued with a NHS or private prescription for a GnRH analogue, whether or not the prescription has been dispensed or the prescribed GnRH analogue has been taken by that person before 19 July 2024; orbis being treated with a GnRH analogue as part of a National Institute for Health and Care Research clinical trial related to treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. 1Treatment for any purpose.2Treatment for any purpose other than treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.3Treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.
Locabiotal Aerosol Any patient Treatment of infections and inflammation of the oropharynx
Niferex Elixir 30ml Paediatric Dropper Bottle Infants born prematurely Prophylaxis and treatment of iron deficiency
Nizoral Cream Any patient Treatment of seborrhoeic dermatitis and pityriasis versicolor
Oseltamivir (Tamiflu) 1A patient ... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where—athe Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;bthe patient has an influenza-like illness; andcthe patient can start therapy within 48 hours of the onset of symptoms.2A patient ... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where—ait has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating;bthe patient has an influenza-like illness; andcthe patient can start therapy within 48 hours of the onset of symptoms.3Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Minsters. Treatment of influenza
Oseltamivir (Tamiflu) 4 A patient ... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—athe Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;bthe patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;cthe patient is not effectively protected by vaccination against influenza because—ihe has not been vaccinated because vaccination is contraindicated;iihe has not been vaccinated since the previous influenza season;iiihe has been vaccinated but it has yet to take effect; orivhe has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;dthe patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; andethe patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.5A patient ... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—ait has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating;bthe patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;cthe patient is not effectively protected by vaccination against influenza because—ihe has not been vaccinated because vaccination is contraindicated;iihe has not been vaccinated since the previous influenza season;iiihe has been vaccinated but it has yet to take effect; orivhe has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;dthe patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; andethe patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.6Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers. Prophylaxis of infinfluenza
The following drugs for the treatment of erectile dysfunction—Alprostadil ...Avanafil... ...... ...Sildenafil ...Tadalafil ...... ...Vardenafil ... 1 The following patients with erectile dysfunction—aa man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland) Act 1978[^f00003] or the Health and Personal Social Services (Northern Ireland) Order 1972[^f00004] for this condition with any of the following drugs—Alprostadil (Caverject), (MUSE), (Viridal)Apomorphine Hydrochloride (Uprima)Moxisylyte Hydrochloride Assembly (Erecnos)Sildenafil (Viagra)Tadalafil (Cialis)Thymoxamine Hydrochloride (Erecnos); orb a man who is a national of an EEA State who—iimmediately before IP completion day was entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 as extended by the EEA Agreement or was entitled to treatment by virtue of any other enforceable EU right,iihas erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for that condition with any of the drugs listed in sub-paragraph (a), andiiiimmediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), orc a man who is not a national of an EEA State but who is the member of the family of such a national and who—iimmediately before IP completion day had an enforceable EU right to be treated no less favourably than the national in the provision of medical treatment,iihas erectile dysfunction and was on 14th September 1998 receiving a course of treatment for that condition with any of the drugs listed in sub-paragraph (a), andiiiimmediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), orda man who is suffering from any of the following—diabetesmultiple sclerosisparkinson’s diseasepoliomyelitisprostate cancersevere pelvic injurysingle geneneurological diseasespina bifidaspinal cord injury; orea man who is receiving treatment for renal failure by dialysis; orfa man who has had the following surgery —prostatectomyradical pelvic surgeryrenal failure treated by transplantga man who has been diagnosed as suffering severe distress resulting from erectile dysfunction where the assessment has been made by a specialist service or GP under arrangements made with a Local Health Board to provide such assessments; Treatment of erectile dysfunction
The following drugs for the treatment of erectile dysfunction—Alprostadil ...Avanafil... ...... ...Sildenafil ...Tadalafil ...... ...Vardenafil ... 2Any patient Treatment of a condition other than erectile dysfunction, in respect of which the drug ordered is in receipt of a UK or EU marketing authorisation for the treatment of that condition
Zanamivir (Relenza) 1 A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza, where—athe Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community;bthe patient has an influenza-like illness; andcin the case of a patient—iwho has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms;iiwho is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.2A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where—ait has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or was present at the time that the virus was circulating;bthe patient has an influenza-like illness; andcin the case of a patient—iwho has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms;iiwho is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms. Treatment of influenza
Zanamivir (Relenza) Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers. Prophylaxis or treatment of influenza

Signed

Signed on behalf of he National Assembly for Wales under section 66(1) of the Government of Wales Act 1998[^f00002]

D. Elis-Thomas — The Presiding Officer of the National Assembly — 30th March 2004

Explanatory note

(This note is not part of the Regulations)

These Regulations make provision as to the drugs, medicines or other substances that may be ordered for patients in the provision of medical services under a general medical services contract within the meaning of section 28Q of the National Health Service Act 1977[^f00009].

Regulation 2 and Schedule 1 list the drugs, medicines and other substances that may not be ordered under such a contract.

Regulation 3 and Schedule 2 specify the drugs, medicines and other substances that may be ordered under such a contract only in certain circumstances and sets out those circumstances.

Footnotes

[^f00001]: 1977 c. 49; section 28U was inserted by section 175(1) of the Health and Social Care (Community Health and Standards) Act 2003 (c. 43) (“the 2003 Act”).

[^f00002]: 1998 c. 38.

[^f00003]: 1978 c. 29.

[^f00004]: S.I. 1972/1265 (NI 14).

[^f00006]: Cm. 2073 and O.J. No. L1, 3.1.1944, p.3.

[^f00007]: Cm. 2183 and O.J.No. L1, 3.1.1994, p.572.

[^f00008]: O.J. No. L160, 28.6. 1996, p.1.

[^f00009]: Section 28Q was inserted into the Act by section 175(1) of the 2003 Act.

Editorial notes

[^key-1896675e059352e04da329123808b411]: Reg. 1 in force at 1.4.2004, see reg. 1(1)

[^key-38f50b8149f7084ae8953900fc9361a9]: Reg. 2 in force at 1.4.2004, see reg. 1(1)

[^key-c072db4403393674539541ea9c4fce8e]: Reg. 3 in force at 1.4.2004, see reg. 1(1)

[^key-bed8f7270f621dc475da4cb977b5514c]: Sch. 1 in force at 1.4.2004, see reg. 1(1)

[^key-d8848619b026971c949cff537d6b7469]: Sch. 2 in force at 1.4.2004, see reg. 1(1)

[^key-091801fd2c4d072bf2931653b1e3aaa8]: Words in Sch. 2 inserted (4.4.2005) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2005 (S.I. 2005/366), regs. 1(1), 2(2)(a)

[^key-eb2bf20629a2474f39faf659d3530095]: Words in Sch. 2 inserted (4.4.2005) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2005 (S.I. 2005/366), regs. 1(1), 2(2)(b)

[^key-25b440c6a5da076886d32b67a433b7fd]: Words in Sch. 2 inserted (10.7.2009) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc) (Wales) (Amendment) Regulations 2009 (S.I. 2009/1838), regs. 1(1), 2(2)(b)

[^key-f43b93a02d6d296ea094c3e2458f7cf1]: Words in Sch. 2 substituted (12.4.2013) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2013 (S.I. 2013/683), regs. 1(1), 2(2)(a)

[^key-7bef46d17ce8d67d50351998ab1b3904]: Words in Sch. 2 inserted (12.4.2013) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2013 (S.I. 2013/683), regs. 1(1), 2(2)(b)

[^key-14108a74b8cdef8f84b75f41ee341a20]: Words in Sch. 2 substituted (12.4.2013) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2013 (S.I. 2013/683), regs. 1(1), 2(2)(c)

[^key-75bfa61c6da97df4b6c65b708d6eb952]: Word in Sch. 2 heading substituted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(a)

[^key-55aad3f886c132456e24c8542b739938]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(i)

[^key-128b2050da86733b01a54bf0778ef708]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(ii)

[^key-7dcc442b682cc80a60d81ada67167754]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(iii)

[^key-f1b9b6c95b077937c0365290527f95c0]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(iv)

[^key-ac443b4c191949ed277628d161eb4b49]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(v)

[^key-5a1ab1f5bd401e965eb437938054207f]: Words in Sch. 2 omitted (14.2.2014) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(b)(vi)

[^key-1e56684d38f586a7d77cf9f4c377c238]: Words in Sch. 2 inserted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(c)(i)

[^key-69ad72410d6b4777185a93eb7f779ec0]: Words in Sch. 2 inserted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(c)(ii)

[^key-f9ff02e9d78bd7bc10274e341b808ad7]: Words in Sch. 2 inserted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(d)

[^key-9e9adac4b9fde3aca9b79bf1f7ca975a]: Words in Sch. 2 omitted (1.3.2016) by virtue of The National Health Service (Primary Medical Services and Primary Dental Services) (Wales) (Amendment and Transitional Provision) Regulations 2016 (S.I. 2016/90), regs. 1(1), 9(a)(i)

[^key-3a7572a244f2f8586d2f30dec17f19aa]: Word in Sch. 2 inserted (1.3.2016) by The National Health Service (Primary Medical Services and Primary Dental Services) (Wales) (Amendment and Transitional Provision) Regulations 2016 (S.I. 2016/90), regs. 1(1), 9(a)(ii)

[^key-8663b637ea8ee3d94b12518f0ba6d117]: Words in Sch. 2 omitted (1.3.2016) by virtue of The National Health Service (Primary Medical Services and Primary Dental Services) (Wales) (Amendment and Transitional Provision) Regulations 2016 (S.I. 2016/90), regs. 1(1), 9(b)

[^key-650f220c61513fa9dc3fbaf1060cf508]: Words in Sch. 2 omitted (1.3.2016) by virtue of The National Health Service (Primary Medical Services and Primary Dental Services) (Wales) (Amendment and Transitional Provision) Regulations 2016 (S.I. 2016/90), regs. 1(1), 9(c)(i)

[^key-b9e35fffd5a89729968c5268e8808f6d]: Words in Sch. 2 inserted (1.3.2016) by The National Health Service (Primary Medical Services and Primary Dental Services) (Wales) (Amendment and Transitional Provision) Regulations 2016 (S.I. 2016/90), regs. 1(1), 9(c)(ii)

[^key-436c33a52626ede34bf6c694458a6d6f]: Words in Sch. 2 substituted (31.12.2020 immediately before IP completion day) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Wales) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1396), regs. 1(2), 2(2)(a)

[^key-f147df1de1a4284bc778d5e215757c18]: Words in Sch. 2 substituted (31.12.2020 immediately before IP completion day) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Wales) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1396), regs. 1(2), 2(2)(b)

[^key-28edbfe2283b8838c708202c985a21c8]: Words in Sch. 2 inserted (19.7.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(2)(a)

[^key-63a73a248eb4d813e6231700041704c3]: Words in Sch. 2 inserted (19.7.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(2)(b)

[^key-eb45d35cd89c1c4d391052f4071de9f3]: Words in Sch. 2 inserted (19.7.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(2)(c)

[^key-72aa385f0288f0ed20f43f7ef99f1cd7]: Words in Sch. 2 omitted (19.7.2024) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(2)(d)

[^key-8d7236354a35d342ec6823fb4333c7a4]: Words in Sch. 2 inserted (19.7.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(3)

[^key-435540f4fb8eb8000a8d9c24e73ea4e4]: Words in Sch. 2 substituted (19.7.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2024 (S.I. 2024/774), regs. 1, 2(4)

[^key-8b5a5d28c7c2c6f2891d093698660a93]: Reg. 1A inserted (15.11.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1065), regs. 1(2), 2(2)

[^key-eb281261c44a58d328c0f7f84d7e02a4]: Words in Sch. 2 substituted (15.11.2024) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1065), regs. 1(2), 2(3)(a)

[^key-d341f90904caafbeb588eddd89c1c0e0]: Words in Sch. 2 omitted (15.11.2024) by virtue of The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1065), regs. 1(2), 2(3)(b)

Interpretation

1A

In these Regulations, “general medical services contract” means a general medical services contract under section 42 of the National Health Service (Wales) Act 2006 (general medical services contracts: introductory).

Drugs, medicines and other substances that may be ordered only in certain circumstances

Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.

This text is published under legislation.gov.uk's own terms of reuse, not a Legalize or public-domain licence. legislation.gov.uk
Open Government Licence v3.0 (attribution required)
© Crown and database right. Derived from content available under the Open Government Licence v3.0 from legislation.gov.uk.